全文获取类型
收费全文 | 5977篇 |
免费 | 429篇 |
国内免费 | 23篇 |
专业分类
耳鼻咽喉 | 46篇 |
儿科学 | 245篇 |
妇产科学 | 148篇 |
基础医学 | 938篇 |
口腔科学 | 54篇 |
临床医学 | 624篇 |
内科学 | 1149篇 |
皮肤病学 | 62篇 |
神经病学 | 723篇 |
特种医学 | 155篇 |
外科学 | 598篇 |
综合类 | 39篇 |
预防医学 | 659篇 |
眼科学 | 80篇 |
药学 | 471篇 |
中国医学 | 26篇 |
肿瘤学 | 412篇 |
出版年
2024年 | 6篇 |
2023年 | 36篇 |
2022年 | 66篇 |
2021年 | 168篇 |
2020年 | 98篇 |
2019年 | 151篇 |
2018年 | 167篇 |
2017年 | 127篇 |
2016年 | 142篇 |
2015年 | 175篇 |
2014年 | 196篇 |
2013年 | 301篇 |
2012年 | 411篇 |
2011年 | 485篇 |
2010年 | 257篇 |
2009年 | 247篇 |
2008年 | 399篇 |
2007年 | 414篇 |
2006年 | 392篇 |
2005年 | 387篇 |
2004年 | 384篇 |
2003年 | 343篇 |
2002年 | 323篇 |
2001年 | 43篇 |
2000年 | 30篇 |
1999年 | 52篇 |
1998年 | 69篇 |
1997年 | 63篇 |
1996年 | 59篇 |
1995年 | 43篇 |
1994年 | 41篇 |
1993年 | 37篇 |
1992年 | 26篇 |
1991年 | 21篇 |
1990年 | 24篇 |
1989年 | 16篇 |
1988年 | 17篇 |
1987年 | 19篇 |
1986年 | 12篇 |
1985年 | 12篇 |
1984年 | 22篇 |
1983年 | 16篇 |
1982年 | 17篇 |
1981年 | 14篇 |
1980年 | 20篇 |
1979年 | 11篇 |
1978年 | 12篇 |
1977年 | 5篇 |
1973年 | 5篇 |
1942年 | 4篇 |
排序方式: 共有6429条查询结果,搜索用时 62 毫秒
91.
The need to consider using dapsone in pregnant women for its antimalarial activity is becoming greater in areas where Plasmodium falciparum resistance to chloroquine and pyrimethamine-sulfadoxine is rapidly increasing. Dapsone in combination with other antimalarials might provide a valuable alternative for both treatment and prophylaxis. This review assesses the clinical pharmacology of dapsone and its adverse drug reactions in relation to haemolysis, glucose-6-phosphate dehydrogenase (G6PD) deficiency, blood dyscrasias and methaemoglobinaemia. Studies are summarised reporting its use in leprosy, dermatological and other conditions, and malaria, in relation to maternal and infant outcomes. A total of 924 pregnancies were identified during which dapsone therapy was taken. Only limited data are available and this precludes a meaningful quantitative benefit-risk analysis.Mild degrees of haemolysis consistently occur with continued therapy, although adverse effects may be less likely with intermittent treatment, as most reported adverse effects have occurred with long-term use of dapsone. There are a number of gaps in knowledge where more data are needed. These include no data on pharmacokinetics in pregnancy and whether these are altered with co-administration of chlorproguanil. Potential complications in women with severe anaemia are unknown and there is no information on haemolytic effects in women or the fetus with G6PD deficiency. The use of dapsone in HIV-infected women in malarious areas could carry increased risks because of the immunosuppressive actions of the drug. Trials of dapsone therapy in pregnancy should be considered in malarious areas where there is good reason for its deployment. Controlled trials have provided data on maternal tolerance, and dapsone in combination with other antimalarial drugs can offer clear benefit in terms of improved birthweight. The use of dapsone combinations should be considered when no good alternative is available and the threat of malaria is the greater risk. 相似文献
92.
The power of positive deviance 总被引:1,自引:0,他引:1
David R Marsh Dirk G Schroeder Kirk A Dearden Jerry Sternin Monique Sternin 《British medical journal》2004,329(7475):1177-1179
93.
94.
95.
96.
97.
98.
Eric A.J. Bleeker Wim H. de Jong Robert E. Geertsma Monique Groenewold Evelyn H.W. Heugens Marjorie Koers-Jacquemijns Dik van de Meent Jan R. Popma Anton G. Rietveld Susan W.P. Wijnhoven Flemming R. Cassee Agnes G. Oomen 《Regulatory toxicology and pharmacology : RTP》2013,65(1):119-125
In recent years, an increasing number of applications and products containing or using nanomaterials have become available. This has raised concerns that some of these materials may introduce new risks for humans or the environment. A clear definition to discriminate nanomaterials from other materials is prerequisite to include provisions for nanomaterials in legislation. In October 2011 the European Commission published the ‘Recommendation on the definition of a nanomaterial’, primarily intended to provide unambiguous criteria to identify materials for which special regulatory provisions might apply, but also to promote consistency on the interpretation of the term ‘nanomaterial’. In this paper, the current status of various regulatory frameworks of the European Union with regard to nanomaterials is described, and major issues relevant for regulation of nanomaterials are discussed. This will contribute to better understanding the implications of the choices policy makers have to make in further regulation of nanomaterials. Potential issues that need to be addressed and areas of research in which science can contribute are indicated. These issues include awareness on situations in which nano-related risks may occur for materials that fall outside the definition, guidance and further development of measurement techniques, and dealing with changes during the life cycle. 相似文献
99.
Anne-Esther Breyton Aurélie Goux Stéphanie Lambert-Porcheron Alexandra Meynier Monique Sothier Laurie VanDenBerghe Olivier Brack Emmanuel Disse Martine Laville Sophie Vinoy Julie-Anne Nazare 《Nutrition, metabolism, and cardiovascular diseases : NMCD》2021,31(1):237-246
Background and aimsIn type 2 diabetes (T2D) patients, the reduction of glycemic variability and postprandial glucose excursions is essential to limit diabetes complications, beyond HbA1c level. This study aimed at determining whether increasing the content of Slowly Digestible Starch (SDS) in T2D patients’ diet could reduce postprandial hyperglycemia and glycemic variability compared with a conventional low-SDS diet.Methods and resultsFor this randomized cross-over pilot study, 8 subjects with T2D consumed a controlled diet for one week, containing starchy products high or low in SDS. Glycemic variability parameters were evaluated using a Continuous Glucose Monitoring System.Glycemic variability was significantly lower during High-SDS diet compared to Low-SDS diet for MAGE (Mean Amplitude of Glycemic Excursions, p < 0.01), SD (Standard Deviation, p < 0.05), and CV (Coefficient of Variation, p < 0.01). The TIR (Time In Range) [140–180 mg/dL[ was significantly higher during High-SDS diet (p < 0.0001) whereas TIRs ≥180 mg/dL were significantly lower during High-SDS diet. Post-meals tAUC (total Area Under the Curve) were significantly lower during High-SDS diet.ConclusionOne week of High-SDS Diet in T2D patients significantly improves glycemic variability and reduces postprandial glycemic excursions. Modulation of starch digestibility in the diet could be used as a simple nutritional tool in T2D patients to improve daily glycemic control.Registration numberin clinicaltrials.gov: NCT 03289494. 相似文献
100.